Rare Sugar Market Size & Share 2026-2035

Rare Sugar Market Size

The rare sugar market was valued at USD 1.4 billion in 2025 and will reach USD 2.4 billion by 2035, expanding at a 5.4% CAGR over 2026–2035. Global revenue reaches USD 1.5 billion in 2026. Rare sugars covered here are D-Mannose, allulose (D-psicose), tagatose, and allose: monosaccharides that occur naturally in trace quantities and are commercially produced through enzymatic conversion, fermentation, or chemical synthesis.

The market has moved beyond a single health-positioning proposition. D-Mannose still supplies the largest revenue pool because pharmaceutical-grade supplement applications command premium prices, while allulose is widening the addressable food and beverage market through lower-calorie formulation and increasingly scalable supply. Tagatose adds a third commercial route: a low-glycemic ingredient with food, pharmaceutical, and nutraceutical relevance. The resulting mix explains why revenue growth moderates from the 7.0% historic CAGR recorded in 2022–2025 even as volume continues to rise.

Scope follows demand-side revenue at the point of sale from rare sugar producers and suppliers to end-use industries. The value chain extends from raw-material production through enzymatic or fermentation processing, rare sugar manufacturing, distribution and formulation, and use in food and beverage, pharmaceuticals, nutraceuticals, cosmetics, and other applications. The market excludes conventional nutritive sugars, sugar alcohols, and specialty carbohydrates outside the four covered rare sugar types.

A triangulated sizing approach combines company capacity and product evidence, application demand, regional demand patterns, and competitive revenue allocation. Market shares and CAGRs are analytical estimates. Regulatory filings, company disclosures, industry developments, and public-health sources anchor the external facts used to assess commercial mechanisms.

Key Drivers

Demand for low-calorie sweeteners is increasing as food manufacturers seek sucrose reduction without abandoning sensory or processing performance. Allulose is commercially consequential because its use case extends beyond sweetness: it can support browning, moisture retention, and freezing-point control in relevant food formats. The World Health Organization’s work on reducing free-sugar intake has strengthened the policy and health context for reformulation.^{[1]World Health Organization, Healthy Diet - who.int} The commercial result is a larger pipeline of beverages, bakery products, confectionery, dairy alternatives, and frozen foods that can justify qualification of a higher-cost ingredient.

Diabetes and obesity add a durable health-related demand driver. The International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projected more than 643 million by 2030.^{[2]International Diabetes Federation, IDF Diabetes Atlas - diabetesatlas.org} This demand does not translate evenly across rare sugars. D-Mannose benefits most directly in urinary-tract-health supplement channels, tagatose is differentiated by a glycemic index of 3, and allulose supports calorie reduction in formulated foods. Suppliers that can provide stability data, regulatory files, and consistent physical specifications are better placed to convert this need into repeat orders.

Clean-label positioning supplies an opportunity rather than a separate market. Enzymatically produced allulose and tagatose can support a naturally derived ingredient narrative, but the commercial value depends on whether the ingredient also solves formulation, labeling, and supply constraints. Enzymatic cascades therefore alter unit economics and market access at the same time. Bonumose’s starch-to-tagatose platform is an example of how process innovation can turn a technically credible ingredient into one suitable for larger-volume food programs.^{[3]Bonumose, Tagatose - bonumose.com}

Key Restraints

*Forecast impacts are directional rather than strictly additive. They reflect baseline growth, mix effects, and interactions among regulation, capacity, price, and application demand.*

Production cost is the principal constraint on broad substitution of conventional sweeteners. Pharmaceutical-grade D-Mannose is priced at USD 8,000–12,000 per ton, while D-Allose ranges from USD 12,000–20,000 per ton. These price points support premium supplements and specialized formulations but narrow the viable customer base for high-volume food products. Capacity additions relieve this pressure for allulose, yet qualification cycles and food manufacturers’ margin requirements limit how quickly lower raw-material costs translate into new product launches.

Regulation also shapes the market at the formulation stage. The U.S. Food and Drug Administration has GRAS notices covering allulose and tagatose, creating a comparatively developed route to market.^{[4]U.S. Food and Drug Administration, GRAS Notice Inventory - fda.gov} In Europe, SAVANNA Ingredients’ allulose application remains within the EU Novel Food process, while its UK application is listed as RP-1130 by the Food Standards Agency. ^{[5]European Commission, Novel Food - food.ec.europa.eu} UK Food Standards Agency ^{[6]UK Food Standards Agency, Regulated Product Application RP-1130 - data.food.gov.uk} The constraint is not solely legal: unresolved approval timing causes food companies to defer product-development resources and reduces the value of local manufacturing capacity until market access is confirmed.

Rare Sugar Market Segment Analysis

By Rare Sugar Type

D-Mannose. D-Mannose generated USD 620.2 million and held 44.3% of market revenue in 2025. Its 1.0% CAGR through 2035 reflects a mature pharmaceutical and dietary-supplement base rather than an absence of demand. The ingredient’s role in urinary tract infection management, along with pharmaceutical-grade purity requirements, supports average pricing near USD 10,000 per ton. Ardilla Technologies produces crystalline D-Mannose at Lapua, Finland through chromatographic separation and crystallization, with ISO 9001, Kosher, and Halal credentials.^{[7]Ardilla Technologies, Rare Sugars and D-Mannose - ardillatech.com} Chinese producers remain important to supply, but D-Mannose lacks an equivalent of allulose’s expanding mainstream food formulation pipeline. Its revenue rises to approximately USD 685 million by 2035 as share falls to 28.5%.

Allulose. Allulose generated USD 428.4 million, or 30.6% of revenue, in 2025 and will grow at an 8.5% CAGR to approximately USD 1,021 million by 2035. U.S. GRAS recognition and exemption from “Total Sugars” and “Added Sugars” labeling create a commercial advantage for reformulated packaged foods. U.S. Food and Drug Administration Supply is broadening through Cargill’s Eddyville operation, Tate & Lyle’s Decatur production, Samyang’s Ulsan capacity, and Chinese producers including Shandong Bailong and Shandong Fuyang. The latter has confirmed D-Allulose capacity of 20,000 tons per year.^{[8]Shandong Fuyang Bio-tech, Company Profile - fuyangbio.com} Allulose combines approximately 70% of sucrose sweetness with 0.4 kcal per gram, supporting food and beverage applications where bulk and texture matter alongside sweetness.

Tagatose. Tagatose accounted for USD 210.0 million and 15.0% share in 2025. It will expand at a 7.2% CAGR to approximately USD 478 million by 2035. Bonumose’s GRAS Notice GRN 977 and its multi-step enzymatic conversion of plant-based starch establish a production foundation for the segment. U.S. Food and Drug Administration Roquette’s July 2024 cooperation agreement with Bonumose connects that technology to large-scale starch-processing infrastructure and a commercial network reaching more than 100 countries.^{[9]Roquette press release, Roquette and Bonumose Global Agreement on Tagatose - roquette.com} The partnership matters because tagatose’s historical constraint has been cost and scale rather than consumer relevance.

Allose. D-Allose accounted for USD 141.4 million and 10.1% share in 2025. The segment will grow at a 4.8% CAGR to approximately USD 216 million by 2035. Its applications remain concentrated in pharmaceutical research and specialty nutraceuticals, where antioxidant and metabolic characteristics support high prices. Industrial-scale production remains limited, keeping the segment oriented toward specialized demand rather than broad food replacement.

By Product Type

Powder/Crystalline. Powder and crystalline formats accounted for USD 908.6 million and 64.9% share in 2025. This form dominates D-Mannose supplements, tablets, capsules, dry blends, and premium food ingredients because it offers dosing precision, shelf stability, and compatibility with established dry processing. Matsutani’s ASTRAEA crystalline allulose and Tate & Lyle’s DOLCIA PRIMA crystalline ingredient demonstrate the format’s role in high-specification applications. Matsutani Chemical Industry ^{[10]Matsutani Chemical Industry, ASTRAEA Allulose - matsutani.co.jp} Tate & Lyle ^{[11]Tate & Lyle, DOLCIA PRIMA Allulose - tateandlyle.com} Growth reaches 4.4% CAGR through 2035 as powder remains commercially important but loses share to liquid formats.

Liquid/Syrup. Liquid and syrup products generated approximately USD 420 million and 30.0% share in 2025. They will expand at a 7.4% CAGR because beverage, bakery, and confectionery lines can incorporate liquid ingredients with fewer process changes than a dry input. Tate & Lyle supplies DOLCIA PRIMA allulose in syrup and crystalline forms, while Samyang produces liquid and crystalline allulose from Ulsan. Tate & Lyle The form is expected to reach approximately USD 882 million and 36.8% share by 2035. Its growth shows that procurement decisions depend on line compatibility and handling economics, not sweetness metrics alone.

Other Product Types. Encapsulated forms, specialty blends, and co-formulated matrices generated approximately USD 71.4 million in 2025. Growth of 4.8% CAGR supports an estimated USD 94 million by 2035. This category serves controlled-release, bioavailability, and proprietary supplement applications where the formulation format carries as much commercial value as the rare sugar itself.

By Application

Food & Beverage. Food and beverage generated USD 861.0 million and 61.5% share in 2025. The segment will reach approximately USD 1,416 million by 2035 at a 4.8% CAGR. Allulose is central because it contributes Maillard browning, moisture retention, and freezing-point depression in addition to calorie reduction. Daesang supplies Sweevero allulose to Coca-Cola Korea for zero-calorie beverage applications.^{[12]Daesang, Sweevero Allulose - daesang.com} The more consequential shift is operational: liquid allulose lets customers reduce sugar without rebuilding liquid handling systems, lowering the qualification hurdle for large food programs.

Pharmaceuticals. Pharmaceuticals accounted for USD 280 million and 20.0% share in 2025. The segment will grow at a 4.3% CAGR to approximately USD 444 million by 2035. D-Mannose remains the largest ingredient because its established urinary-tract-health role fits supplement and pharmaceutical-adjacent channels. Tagatose adds a lower-glycemic option as availability expands. Pharmaceutical-grade purity, documentation, and repeatable particle and moisture specifications keep this segment less exposed to the price compression that is reshaping food-grade allulose.

Nutraceuticals. Nutraceuticals generated USD 112 million and 8.0% share in 2025, with the fastest application CAGR at 7.5%. Revenue is expected to reach approximately USD 264 million by 2035. Metabolic wellness, gut health, weight management, protein powder, and meal-replacement formats expand demand for ingredients positioned as functional actives rather than passive sweeteners. This channel also gives suppliers a route to preserve value as allulose’s food-grade price falls.

Cosmetics. Cosmetics accounted for USD 98 million and 7.0% share in 2025, rising at a 6.2% CAGR to approximately USD 192 million by 2035. Japan and South Korea lead use in premium functional cosmetics, where rare sugars can be formulated as humectants, hydration agents, and skin-conditioning ingredients. Matsutani’s established Japanese rare sugar presence provides a commercial anchor in this application space. Matsutani Chemical Industry

Other Applications. Animal feed additives, fermentation substrates, and industrial uses represented USD 49 million and 3.5% share in 2025. The segment will grow at 4.5% CAGR to approximately USD 84 million by 2035. Demand remains secondary to food, supplements, and pharmaceutical applications because price sensitivity is higher and functional differentiation is less easily monetized.

Rare Sugar Market Regional Analysis

By Region

North America

North America generated USD 461.7 million and 33.0% share in 2025, including USD 384 million from the United States. The region will grow at a 4.5% CAGR to USD 718.2 million by 2035. U.S. GRAS pathways, allulose labeling treatment, and domestic production by Cargill in Iowa, Tate & Lyle in Illinois, and Bonumose in Virginia underpin the mature market. U.S. Food and Drug Administration Canada contributes imported ingredient demand tied to clean-label food and supplement adoption. North America’s limitation is maturity: D-Mannose demand is established, so regional growth increasingly depends on allulose adoption in larger food categories.

Europe

Europe generated USD 333.2 million and 23.8% share in 2025 and will reach USD 542.8 million by 2035 at a 5.0% CAGR. Germany leads through functional-ingredient demand and SAVANNA Ingredients’ Elsdorf allulose operation. The UK, France, Spain, and Italy provide secondary demand centers. Europe’s commercial constraint is regulatory timing: EU Novel Food and UK assessment processes determine when domestic allulose capacity can fully address local food manufacturers. European Commission Roquette’s French base and tagatose agreement with Bonumose give the region a separate route to rare-sugar scale-up.

Asia Pacific

Asia Pacific generated USD 387.9 million and 27.7% share in 2025. It is the fastest-growing region at 7.1% CAGR and will reach USD 771.9 million by 2035. South Korea’s production base includes Samyang’s Ulsan facility and Daesang’s Gunsan operation. Samyang completed Ulsan in September 2024 with 25,000 tons of total specialty capacity, including 13,000 tons of allulose capacity, after KRW 140 billion of investment. Samyang Corporation announcement ^{[13]Samyang Corporation press release, Samyang Corporation Completes Specialty Plant - prnewswire.com} China combines Shandong Bailong’s allulose and D-Mannose portfolio with Shandong Fuyang’s 20,000-ton D-Allulose capacity. Shandong Bailong Chuangyuan Bio-tech ^{[14]Shandong Bailong Chuangyuan Bio-tech, Allulose - bailongcn.com} Japan supports premium allulose through Matsutani, while Australia and New Zealand cleared Daesang’s Sweevero allulose in 2024. Daesang announcement India adds long-term demand potential through its large diabetic population. International Diabetes Federation

Latin America

Latin America generated USD 149.8 million and 10.7% share in 2025 and will rise at a 5.4% CAGR to USD 253.7 million by 2035. Brazil leads regional demand through health-food adoption, a growing middle class, and diabetes prevalence. Mexico’s obesity and diabetes-management focus raises awareness of lower-calorie sweeteners, while Argentina represents a smaller developing market. Imported supply and price sensitivity remain constraints because rare sugar production is concentrated outside the region.

Middle East & Africa

Middle East and Africa generated USD 67.2 million and 4.8% share in 2025, rising at a 5.4% CAGR to USD 113.4 million by 2035. Saudi Arabia leads, supported by health and wellness initiatives under Vision 2030 and substantial diabetes prevalence. The UAE provides a premium imported-ingredient market, while South Africa anchors African demand. Lower awareness, limited localized regulatory pathways for allulose, and reliance on imports hold the region below the growth rate of Asia Pacific.

Rare Sugar Market Share & Competitive Landscape

The market is moderately fragmented. Cargill led with 12.4% share in 2025, and the top five companies collectively held 27.1%. The remaining 72.9% is distributed among specialized manufacturers, brand owners and distributors, and a large group of Chinese producers. Fragmentation reflects different production technologies, regulatory positions, product formats, and end-use specialization rather than a lack of large ingredient companies.

Cargill’s leadership rests on vertical integration from corn sourcing through processing and distribution. Its rare sugar product is Cargill Allulose, not EverSweet; EverSweet is a stevia product made through the Avansya joint venture. Cargill Avansya Tate & Lyle differentiates through production of both crystalline and syrup allulose in Decatur and through its allulose intellectual-property portfolio. Tate & Lyle Matsutani pairs long rare-sugar experience with ASTRAEA production in Querétaro, Mexico, using a proprietary D-allulose 3-epimerase. Matsutani Chemical Industry

Samyang is the most consequential projected share gainer. Its share is expected to rise from 3.0% in 2025 to 5.5% by 2035 as the Ulsan asset gives it material liquid and crystalline allulose capacity. Roquette is expected to rise from 3.7% to 4.5% as tagatose commercialization scales with Bonumose. Cargill’s share is projected to moderate to 10.5%, not because of operational weakness, but because the market’s allulose supply base will become less concentrated.

Recent Industry Developments

Sep 2024: Samyang completed the Ulsan specialty plant in South Korea with 25,000 tons of total capacity and 13,000 tons of allulose capacity after KRW 140 billion of investment. Samyang Corporation announcement The asset enlarges exportable allulose supply and increases price competition in liquid and crystalline formats.

Jul 2024: Roquette and Bonumose signed a global cooperation agreement to scale tagatose. Roquette The agreement connects proprietary enzymatic technology with established starch-processing scale.

Jan 2024: The Australian Patent Office upheld Tate & Lyle’s allulose syrup patent claims. Tate & Lyle The decision reinforces the company’s formulation and production intellectual-property position.

2024: Daesang obtained Australian and New Zealand clearance for Sweevero allulose. Daesang announcement The clearance adds APAC export markets to Daesang’s Korean production platform.